Table 3.
SCD-plus criteria and the risk of preclinical AD in individuals with available amyloid status (n = 114)
| Predictor | Data availability (n) | Prevalence of SCD-plus criteriaa | Risk of preclinical ADb | ||
|---|---|---|---|---|---|
| in group with known amyloid status (n = 114) | Preclinical AD (n = 28) | Amyloid negative (n = 86) | Univariate model | Multivariate stepwise model | |
| Memory specific decline | 94 | 13 (59%) | 37 (51%) | 1.4 (0.5–3.6) | – |
| Onset < 5 years | 111 | 12 (46%) | 43 (51%) | 0.8 (0.3–2.0) | – |
| Age ≥ 60 years | 114 | 26 (93%) | 54 (63%) | 7.7 (1.7–34.6) | 3.8 (1.7–20.4) |
| Experience of worse performance than others | 90 | 13 (65%) | 44 (63%) | 1.1 (0.4–3.1) | – |
| Informant reports decline | 97 | 15 (60%) | 32 (44%) | 1.9 (0.7–4.7) | – |
| APOE e4 carriership | 110 | 17 (65%) | 23 (27%) | 5.0 (2.0–12.8) | 6.2 (1.7–22.2) |
AD Alzheimer’s disease, APOE apolipoprotein E (genotype), SCD subjective cognitive decline
aPrevalence of each SCD-plus criterion in individuals with and without preclinical AD, presented as n (%), within cases with amyloid status available (n = 114)
bRisk of preclinical AD separately (univariate models) for each SCD-plus criterion and independent predictors of preclinical AD in a multivariate stepwise model in SCIENCe participants with available amyloid status (n = 114), presented as odds ratio (95% confidence interval)